Logo image
Back
Lecanemab and amyloid-related imaging abnormalities: Real-world data from a single center experience
Journal article   Open access   Peer reviewed

Lecanemab and amyloid-related imaging abnormalities: Real-world data from a single center experience

Alexander Wallace, Oliver Zhou, Minh-Nguyet Hoang, Gabriella Porter, Claudia Padilla and Cindy Marshall
Alzheimer's & dementia : diagnosis, assessment & disease monitoring, Vol.18(2), 70377
05/21/2026
DOI: 10.1002/dad2.70377
PMCID: PMC13239854
PMID: 42255953
Appears in  UI Libraries Support Open Access
url
https://doi.org/10.1002/dad2.70377View
Published (Version of record) Open Access

Abstract

INTRODUCTION Lecanemab has demonstrated both safety and efficacy in clinical trials; however, routine clinical data are sparse. We contribute to the growing body of real-world safety data, with a special focus on amyloid-related imaging abnormalities (ARIA). METHODS We conducted a retrospective chart review of 146 patients treated with lecanemab according to appropriate-use recommendations at a specialty memory center clinic. RESULTS Real-world safety and efficacy data closely resemble published data in the Clarity-AD trial. Thirty-three patients (23%) discontinued treatment; all remaining patients completed at least 12 months of treatment. We observed a positive trend toward increasing ARIA edema/effusion (ARIA-E) with increasing mean arterial pressure and a mean amyloid clearance of -90.6 at 18 months. DISCUSSION When used according to appropriate-use recommendations, lecanemab is as safe as reported in the Clarity-AD trial. Further investigation into real-world data is necessary for a more complete evaluation of lecanemab's safety and efficacy.
 Magnetic Resonance Imaging Alzheimer's disease amyloid plaque clearance amyloid-related imaging abnormalities (ARIA) anti-amyloid monoclonal antibodies APOE ε4 lecanemab real-world data UIOWA OA Agreement

Details

Metrics

3 Record Views
Logo image